Loading...
Please wait, while we are loading the content...
Similar Documents
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
| Content Provider | Scilit |
|---|---|
| Author | Lortholary, Olivier Chandesris, Marie Olivia Livideanu, Cristina Bulai Paul, Carle Guillet, Gérard Jassem, Ewa Niedoszytko, Marek Barete, Stéphane Verstovsek, Srdan Grattan, Clive Damaj, Gandhi Canioni, Danielle Fraitag, Sylvie Lhermitte, Ludovic Lavialle, Sophie Georgin Frenzel, Laurent Afrin, Lawrence B. Hanssens, Katia Agopian, Julie Gaillard, Raphael Kinet, Jean-Pierre Auclair, Christian Mansfield, Colin Moussy, Alain Dubreuil, Patrice Hermine, Olivier |
| Copyright Year | 2017 |
| Description | Journal: The Lancet |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985971/pdf http://www.thelancet.com/article/S0140673616314039/pdf |
| Ending Page | 620 |
| Page Count | 9 |
| Starting Page | 612 |
| ISSN | 01406736 |
| DOI | 10.1016/s0140-6736%2816%2931403-9 |
| Journal | The Lancet |
| Issue Number | 10069 |
| Volume Number | 389 |
| Language | English |
| Publisher | Elsevier BV |
| Publisher Date | 2017-02-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: The Lancet General Medicine Quality of Life Systemic Mastocytosis Primary Endpoint Cumulative Response Severely Symptomatic Indolent |
| Content Type | Text |
| Resource Type | Article |
| Subject | Medicine |